Endocrine Abstracts

Introduction: Smoking harms women more than men and women seem to be less successful in quitting. Greater concerns about post-cessational weight in women and gender differences in craving and reward processing have been postulated as possible explanations. Our group recently showed that the GLP-1 analogue dulaglutide reduces post-cessational weight gain. We hypothesize that women compared to men might profit more from the weight-lowering effects of dulaglutide in terms of abst...

Introduction: Alcohol use disorder AUD causes high socio-economic costs and has a detrimental impact on health globally, being considered a key risk factor for non-communicable diseases. In Switzerland, four substances are currently approved for treatment of AUD, with varying effects. Taking into consideration the complex nature of the disease and the heterogeneity of affect patients, it becomes evident that there is need for new treatment targets. A body of preclinical studie...

Background: GLP-1 analogs are prescribed for diabetes and obesity due to their well-known insulinotropic, satiation-promoting and appetite-suppressant effects. Several studies also investigated the effects of GLP-1 analogs on reward to addictive drugs such as alcohol, nicotine and cocaine. Pre-clinical studies suggest that sexual desire, as another type of natural reward, could also be affected by GLP-1 analogs. Since sexuality is a very important aspect of human wellbeing and...

Introduction: Fluid restriction (FR) is often the recommended first-line treatment for hyponatremia due to the syndrome of inappropriate antidiuresis (SIAD). However, FR not always leads to successful correction of hyponatremia, making predictive markers of treatment response desirable. The aim of this study was to evaluate routinely measured laboratory parameters, copeptin and pro-atrial natriuretic peptide (pro-ANP) as possible predictors of treatment success to FR.<p cl...

Background: Cigarette smoking is the leading preventable cause of premature death. Smoking cessation is one of the central goals in medicine, but despite dedicated programs, quit rates remain low due to barriers such as nicotine withdrawal syndrome or post-cessation weight gain. Glucagon-like peptide-1 (GLP-1) analogues reduce energy intake and body weight and seem to modulate addictive behavior. These GLP-1 properties are of major interest in the context of smoking cessation....